Details for Patent: 9,649,456
✉ Email this page to a colleague
Which drugs does patent 9,649,456 protect, and when does it expire?
Patent 9,649,456 protects ONZETRA XSAIL and is included in one NDA.
This patent has three patent family members in two countries.
Summary for Patent: 9,649,456
| Title: | Nasal administration |
| Abstract: | A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece (47) for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit (16) which is operable to deliver the powdered substance through the nosepiece (47). |
| Inventor(s): | Djupesland; Per Gisle (Oslo, NO), Hafner; Roderick Peter (Swindon, GB) |
| Assignee: | OptiNose AS (Oslo, NO) |
| Application Number: | 12/594,365 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; Device; Dosage form; |
Drugs Protected by US Patent 9,649,456
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ACUTE TREATMENT OF MIGRAINE | ⤷ Try a Trial | |||
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY | ⤷ Try a Trial | |||
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,649,456
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0706744.0 | Apr 5, 2007 |
| PCT Information | |||
| PCT Filed | April 07, 2008 | PCT Application Number: | PCT/GB2008/001226 |
| PCT Publication Date: | October 16, 2008 | PCT Publication Number: | WO2008/122795 |
International Family Members for US Patent 9,649,456
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| United Kingdom | 0706744 | ⤷ Try a Trial | |||
| United Kingdom | 2448183 | ⤷ Try a Trial | |||
| World Intellectual Property Organization (WIPO) | 2008122795 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
